title: Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group.
abstract: OBJECTIVE
  This double-blind, dose-response study was conducted to assess the safety and efficacy of four oral doses of dolasetron mesylate for preventing acute emesis in cancer patients receiving their first course of moderately emetogenic platinum-containing chemotherapy.
  
  
  METHODS
  Patients were randomized to receive a single oral dose of 25, 50, 100, or 200 mg dolasetron 30 minutes before receiving IV carboplatin (275-400 mg/m2)- or cisplatin (20-50 mg/m2)-containing chemotherapy, then monitored for nausea and vomiting for 24 hours.
  
  
  RESULTS
  Three hundred seven cancer patients from 32 sites completed the study. There was a statistically significant dose response across the four doses for complete response (no emetic episodes or rescue medication): 44.7%, 71.3%, 73.2%, and 82.5% for the 25, 50, 100, or 200 mg doses of dolasetron, respectively. Patients' nausea severity and patient satisfaction visual analogue scale scores also showed a statistically significant trend with dose. All doses of dolasetron were well tolerated. The most common adverse events were headache (17.6%) and dizziness (2.0%).
  
  
  CONCLUSIONS
  This study demonstrates the safety and antiemetic efficacy of oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy with the highest antiemetic activity observed at 200 mg.
authors.affiliation: Forsyth Hematology-Oncology Association, Winston-Salem, NC 27103, USA.
authors.forename: T H
authors.initials: TH
authors.lastname: Grote
authors.forename: L F
authors.initials: LF
authors.lastname: Pineda
authors.forename: R A
authors.initials: RA
authors.lastname: Figlin
authors.forename: K B
authors.initials: KB
authors.lastname: Pendergrass
authors.forename: P J
authors.initials: PJ
authors.lastname: Hesketh
authors.forename: B Y
authors.initials: BY
authors.lastname: Karlan
authors.forename: J A
authors.initials: JA
authors.lastname: Reeves
authors.forename: L L
authors.initials: LL
authors.lastname: Porter
authors.forename: C R
authors.initials: CR
authors.lastname: Benedict
authors.forename: W F
authors.initials: WF
authors.lastname: Hahne
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003710:Demography; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011807:Quinolizines / Q000627:therapeutic use*; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D007211:Indoles; D011807:Quinolizines; C060344:dolasetron; D016190:Carboplatin; D002945:Cisplatin